A single dose of a chromium-enriched glucomannan-fructo-oligosaccharide fiber complex significantly reduced postprandial ...

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in emerging markets.

We have five products that will launch in the next 12-18 months. We recently launched Yesintek in the immunology space -- a ...

In general, insulins used in children are rapid-acting insulin analogs, short-acting insulin, intermediate-acting insulin (NPH and Lente), and long-acting insulin analogs. These insulins are used ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

The Affordable Insulin Now Act, as it is known ... combining the effects of GLP-1 with other treatments, such as with an analogue of the hormone amylin, to improve outcomes in type 2 diabetes.

Sometimes, the right advances in medicine catch the public’s imagination—opening a world of possibilities that inspires ...

With the new NHS 10 year plan coming this summer, coinciding with phase 2 of the spending review, questions are being asked about what direction or priorities the NHS will pursue.12 Health secretary ...

The human brain makes up only 2% of our body weight. Yet it burns through 20% of our daily energy budget. That’s around 0.3 ...

and insulin pumps, which also make therapy more convenient, are already gaining in popularity. Novo Nordisk is investing heavily in another oral formulation: its next-generation GLP-1 analogue ...

Shares of Metsera, Inc. (MTSR) soared 12% on Monday after the company announced positive topline data from an early-stage ...

Cantor Fitzgerald upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) to a strong-buy rating in a report ...